Abstract:DNA interstrand crosslinks (ICLs) are among the most toxic types of damage to a cell. For this reason, many ICL-inducing agents are effective therapeutic agents. For example, cisplatin and nitrogen mustards are used for treating cancer and psoralen plus UVA (PUVA) is useful for treating psoriasis. However, repair mechanisms for ICLs in the human genome are not clearly defined. Previously, we have shown that MSH2, the common subunit of the human MutSalpha and MutSbeta mismatch recognition complexes, plays a role in the error-free repair of psoralen ICLs. We hypothesized that MLH1, the common subunit of human MutL complexes, is also involved in the cellular response to psoralen ICLs. Surprisingly, we instead found that MLH1-deficient human cells are more resistant to psoralen ICLs, in contrast to the sensitivity to these lesions displayed by MSH2-deficient cells. Apoptosis was not as efficiently induced by psoralen ICLs in MLH1-deficient cells as in MLH1-proficient cells as determined by caspase-3/7 activity and binding of annexin V. Strikingly, CHK2 phosphorylation was undetectable in MLH1-deficient cells, and phosphorylation of CHK1 was reduced after PUVA treatment, indicating that MLH1 is involved in signaling psoralen ICL-induced checkpoint activation. Psoralen ICLs can result in mutations near the crosslinked sites; however, MLH1 function was not required for the mutagenic repair of these lesions, and so its signaling function appears to have a role in maintaining genomic stability following exposure to ICL-induced DNA damage. Distinguishing the genetic status of MMR-deficient tumors as MSH2-deficient or MLH1-deficient is thus potentially important in predicting the efficacy of treatment with psoralen and perhaps with other ICL-inducing agents.

MED1, a novel human methyl-CpG-binding endonuclease, interacts with DNA mismatch repair protein MLH1

DNA Mismatch Repair Preferentially Protects Genes from Mutation.

Human Exonuclease 1 Functionally Complements Its Yeast Homologues in DNA Recombination, RNA Primer Removal, and Mutation Avoidance*

The Mlh1-Pms1 endonuclease uses ATP to preserve DNA discontinuities as strand discrimination signals to facilitate mismatch repair

Elevated MSH2 MSH3 expression interferes with DNA metabolism in vivo

MRE11A: a novel negative regulator of human DNA mismatch repair

The mismatch DNA repair heterodimer, hMSH2|[sol]|6, regulates BLM helicase

The mismatch DNA repair heterodimer, hMSH2/6, regulates BLM helicase

Acetylation of MLH1 by CBP increases cellular DNA mismatch repair activity

Direct Association of Bloom'S Syndrome Gene Product with the Human Mismatch Repair Protein Mlh1

Elucidation of multiple high-resolution states of human MutSβ by cryo-EM reveals interplay between ATP/ADP binding and heteroduplex DNA recognition

The LSH/DDM1 Homolog MUS-30 Is Required for Genome Stability, but Not for DNA Methylation in Neurospora crassa

Role of mammalian Mre11 in classical and alternative nonhomologous end joining

MLH1 Deficiency-Triggered DNA Hyperexcision by Exonuclease 1 Activates the cGAS-STING Pathway

High rate of CAD gene amplification in human cells deficient in MLH1 or MSH6

Msc1 is a nuclear envelope protein that reinforces DNA repair in late mitosis

NucS-promoted DNA mismatch repair involves limited resection by a 5’-3’ exonuclease and is independent of homologous recombination and NHEJ

Human MLH1 Protein Participates in Genomic Damage Checkpoint Signaling in Response to DNA Interstrand Crosslinks, While MSH2 Functions in DNA Repair.

Mycobacterium smegmatis NucS-promoted DNA mismatch repair involves limited resection by a 5′-3′ exonuclease and is independent of homologous recombination and NHEJ

The Dmc1 recombinase physically interacts with and promotes the meiotic crossover functions of the Mlh1-Mlh3 endonuclease

Mismatch repair enzymes regulate telomere recombination in Saccharomycescerevisiae